Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project

• Published in: The International journal of drug policy Vol. 72; pp. 61 - 68
• Main Authors: Rojas Rojas, Teresa, Di Beo, Vincent, Delorme, Jessica, Barre, Tangui, Mathurin, Philippe, Protopopescu, Camelia, Bailly, François, Coste, Marion, Authier, Nicolas, Carrieri, Maria Patrizia, Rolland, Benjamin, Marcellin, Fabienne
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2019; Elsevier Science Ltd; Elsevier
• Subjects: Adult; Antiviral Agents - administration & dosage; Antiviral drugs; Barrier to care; Databases, Factual; Delivery of Health Care - organization & administration; Direct acting antivirals; Discrimination; Drug policy; Female; France; Health care; Health Services Accessibility; Healthcare Disparities - statistics & numerical data; Hepatitis; Hepatitis C; Hepatitis C virus; Hepatitis C, Chronic - drug therapy; Human health and pathology; Humans; Hépatology and Gastroenterology; Infections; Interferon; Interferons - administration & dosage; Life Sciences; Male; Marginality; Medical treatment; Methadone; Middle Aged; Narcotics; Opioid agonist therapy; Opioid-Related Disorders - epidemiology; Opioid-Related Disorders - therapy; Opioids; Pegylated interferon; Prevention; Primary care; Primary Health Care - organization & administration; Prisoners; Santé publique et épidémiologie; Sex Factors; Sexism; Stigma; Substance abuse treatment; Uptake; Women; France; Women; Direct acting antivirals; Opioid agonist therapy; Hepatitis C virus; Pegylated interferon; Barrier to care

[Display omitted] In the era of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection, HCV treatment uptake remains insufficiently documented in key populations such as people with opioid dependence. Access to opioid agonist therapy (OAT) is facilitated in France thro...